Pneumotox » Drug » Hydroxyurea (hydroxycarbamide)

Hydroxyurea (hydroxycarbamide)

2

Recent review of ILD cases Girard A.et al.[Hydroxyurea-induced pneumonia] Rev Mal Respir, 2014

Last update : 05/02/2014

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

1

I.b Pneumonitis (ILD)

2

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

-

I.g Pulmonary fibrosis

1

II.b ARDS - Acute lung injury

1

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

1

XV.a Path: NSIP-cellular pattern (see also Ia, Ib)

1

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

1

XV.e Path: ILD with a granulomatous component (see also Im)

1

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

1

XV.k Path: Desquamative interstitial pneumonia (DIP-pattern)

1

Diagnosing DIRD

1

Drug and radiation history

2

Drug singularity - Correct identification of the drug

3

Consistent timing of exposure v. onset of symptoms

4

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

5

Careful exlusion of another cause

6

Remission of symptoms with removal of drug

7

Recurrence with rechallenge (rarely advisable)

8

Causality assessment

More detailed checklist